Acacia Pharma: Eagle closes on $104M Acacia acquisition

The move adds two FDA-approved products to the Woodcliff Lake-based company†s portfolio: Barhemsys, used for the treatment of postoperative nausea and vomiting, and Byfavo, for procedural sedation in adults. The post Eagle closes on $104M Acacia acquisition appeared first on NJBIZ.